{
  "id": "64463a5057b1c7a315000064",
  "type": "list",
  "question": "What are the types of Spinal Muscular Atrophy?",
  "ideal_answer": "The types of Spinal Muscular Atrophy are: SMA type 1, SMA type 2, SMA type 3, SMA type 4, X-linked SMA and SMA with respiratory distress.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
    "http://www.ncbi.nlm.nih.gov/pubmed/1389561",
    "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
    "http://www.ncbi.nlm.nih.gov/pubmed/16750368",
    "http://www.ncbi.nlm.nih.gov/pubmed/34878390",
    "http://www.ncbi.nlm.nih.gov/pubmed/33357591",
    "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
    "http://www.ncbi.nlm.nih.gov/pubmed/35466947",
    "http://www.ncbi.nlm.nih.gov/pubmed/35707597",
    "http://www.ncbi.nlm.nih.gov/pubmed/14704958",
    "http://www.ncbi.nlm.nih.gov/pubmed/35284988",
    "http://www.ncbi.nlm.nih.gov/pubmed/33357593",
    "http://www.ncbi.nlm.nih.gov/pubmed/27890489",
    "http://www.ncbi.nlm.nih.gov/pubmed/31274514",
    "http://www.ncbi.nlm.nih.gov/pubmed/16865356",
    "http://www.ncbi.nlm.nih.gov/pubmed/26260993"
  ],
  "snippets": [
    {
      "text": "SMA with a clinical diagnosis of SMA types\u00a01, 2, or 3",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35284988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In phase\u00a02/3 clinical trials, risdiplam significantly improved motor function in infants with SMA type\u00a01 and in patients aged 2-25\u00a0years with SMA types 2 or 3.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35284988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adulthood-onset SMA (SMA type 4) is rare, with few isolated cases reported.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Twenty patients with SMA type 4 were identified in a Brazilian cohort of 227 patients with SMA. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study represents the largest cohort of patients with SMA type 4 and provides functional, genetic, radiological and neurophysiological features ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adolescent and adult patients with SMA types 3 and 4",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35466947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We found no evidence for the contribution of motor unit and capillary recruitment capacity of the upper arm muscles in adolescent and adult patients with SMA types 3 and 4 as primary limiting factors to premature fatigue during execution of a maximal arm-cycling task.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35466947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report a long-term follow-up in adolescent and adult patients with SMA types 1 and 2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nusinersen-treated patients with SMA types 1 and 2 between 2017 and 2022 were retrospectively reviewed. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Seven patients with SMA (type 1, 1; type 2, 6) with a median age of 23 (range, 12-40)years were treated with nusinersen for 3.55 (1.78-4.53)years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/36335004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "On October 1st, 666 patients have been enrolled (357 children and 309 adults) by 44 out of 51 open centers of the national network (FILNEMUS) with: 150 type 1 (22%); 278 type 2 (42%), 232 type\u00a03 (35%) and 4 type 4 (1%) respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34878390",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The identification of the underlying gene defects for familial ALS, spinal muscular atrophy (SMA), and spinal muscular atrophy with respiratory distress (SMARD) has pointed to distinct pathophysiological mechanisms that are responsible for the various forms of the disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14704958",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Interestingly, UBA1 mutations can also cause infantile-onset X-linked spinal muscular atrophy (XL-SMA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The mutation identified here and the XL-SMA causative mutations were shown to affect amino acids positioned in the vicinity of UBA1's ATP binding site and to cause structural changes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The contribution of this same gene to the etiology of XL-SMA is discussed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35996994",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Type I spinal muscular atrophy has been subdivided into 3 groups: - type IA, the clinical signs of which set in between birth and 15 days of life with sudden severe motor impairment, sucking-swallowing disorders attesting to bulbar involvement, respiratory distress.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33357591",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The childhood form of the spinal muscular atrophy (SMA) is classically subdivided into three groups on the basis of a combination of age of onset, milestones of development and age of survival: acute Werdning-Hoffmann (type I), intermediate Werdnig-Hoffmann (type II) and Kugelberg-Welander disease (type III).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1389561",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Spinal muscular atrophy type 3 (SMA3), also called Kugelberg-Welander SMA, typically presents with muscle fatigue, slowly progressive weakness and atrophy of lower limbs once they have already acquired independent ambulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33357593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Spinal muscular atrophy, X-linked 2 (SMAX2) is a rare type of spinal muscular atrophy characterized by muscle weakness, hypotonia, areflexia, myopathic face, tongue fibrillations, contractures, bone fractures, and cryptorchidism.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35707597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SMA is classified in three clinical types, SMA I, SMA II, and SMA III, based on the severity of the symptoms and the age of onset.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16865356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ring seated upper limb tasks in patients with spinal muscular atrophy types 2 and 3.DESIGN: Seventeen persons with spinal muscular atrophy and 15 heal",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31274514",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tional ability in children with non-ambulant spinal muscular atrophy types 2 and 3 in a longitudinal multi-center clinical trial. This study assessed ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16750368",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND & AIMS: Different neuromuscular functional domains in types I and II Spinal Muscular Atrophy (SMAI and SMAII) could lead to differences in body composition (BC) and resting energy expenditure (REE)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27890489",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "SMA type 1, Spinal Muscular Atrophy type 1, SMA 1, SMA type 2, Spinal Muscular Atrophy type 2, SMA 2, SMA type 3, Spinal Muscular Atrophy type 3, SMA 3, SMA type 4, Spinal Muscular Atrophy type 4, SMA 4, spinal muscular atrophy with respiratory distress, SMARD, X-linked Spinal Muscular Atrophy, XL-SMA"
}